Strategic Collaborations Theravance Biopharma has an established FDA-approved product, YUPELRI, and notable collaboration with Viatris, creating a channel for co-marketing and expanded field access in COPD therapies. Sales opportunities exist in leveraging Viatris’ distribution footprint and pharmacovigilance capabilities to broaden patient reach and payer coverage.

Financial Stability With substantial funding and multi-year revenue streams reported from Viatris collaboration (revenue around tens of millions quarterly) alongside a healthy cash position, there is capacity for later-stage programs or strategic deals, suggesting resilience in pursuing new partnerships or licensing of adjunctive therapies.

Pipeline Opportun A pipeline of internally discovered programs targeting unmet needs in specialty respiratory and neurologic diseases indicates ongoing business development potential for licensing partnerships, co-development, or strategic investments to accelerate patient access to novel therapies.

Market Positioning As the developer of a niche COPD inhalation therapy and with competitive landscape awareness including major players, Theravance can position sales initiatives around differentiation, real-world evidence, and payer-focused access strategies to defend share and attract co-promotion opportunities.

Global Footprint Having offices in the United States and Ireland and a diversified tech stack (Cloud, analytics, AI tools) supports global clinical and commercial operations, enabling targeted market expansion, regional partnerships, and streamlined remote engagement with customers and providers.